The strong male predominance in oesophageal adenocarcinoma (OAC) and Barrett’s oesophagus (BO) continues to puzzle. Hormonal influence, e.g. oestrogen or oxytocin, might contribute.
This genetic-epidemiological study pooled 14 studies from three continents, Australia, Europe, and North America. Polymorphisms in 3 key genes coding for the oestrogen pathway (receptor alpha (ESR1), receptor beta (ESR2), and aromatase (CYP19A1)), and 3 key genes of the oxytocin pathway (the oxytocin receptor (OXTR), oxytocin protein (OXT), and cyclic ADP ribose hydrolase glycoprotein (CD38)), were analysed using a gene-based approach, versatile gene-based test association study (VEGAS).
Among 1508 OAC patients, 2383 BO patients, and 2170 controls, genetic variants within ESR1 were associated with BO in males (p = 0.0058) and an increased risk of OAC and BO combined in males (p = 0.0023). Genetic variants within OXTR were associated with an increased risk of BO in both sexes combined (p = 0.0035) and in males (p = 0.0012). We followed up these suggestive findings in a further smaller data set, but found no replication. There were no significant associations between the other 4 genes studied and risk of OAC, BO, separately on in combination, in males and females combined or in males only.
Citation: Lagergren K, Ek WE, Levine D, Chow W-H, Bernstein L, Casson AG, et al. (2015) Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett’s Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium. PLoS ONE 10(9): e0138738. https://doi.org/10.1371/journal.pone.0138738
Editor: Hiromu Suzuki, Sapporo Medical University, JAPAN
Received: May 21, 2015; Accepted: September 1, 2015; Published: September 25, 2015
This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication
Data Availability: Data for which the authors have IRB permission to make public are available from the dbGaP database (accession numbers phs000869.v1.p1 & phs000187.v1.p1). Genotyping data on all participants not included in phs000187.v1.p1 are from the BEACON GWAS of EA and BE, whose authors may be contacted at email@example.com. The small fraction of data that were not uploaded to dbGaP was excluded because of ethical restrictions imposed by the IRB of the Fred Hutchinson Cancer Research Center. These restrictions were based on reviewing all of the informed consents versions signed by the participants, and determining whether the consent was consistent with allowing public sharing such as in dbGaP. Access to any part of the minimal dataset that is not already available publically (in dbGaP) is also restricted legally, via the BEAGESS Collaboration Agreement that was signed by the appropriate official of each participating institution. The original institution or principal investigator that carried out the study still owns the data. Access to the complete minimal dataset (at Fred Hutchinson Cancer Research Center) is commonly done, but is contingent on approval by each relevant principal investigator of access to data. This is true for internal investigators as well as external. They can be contacted through the Chair of the Steering Committee of BEACON and BEAGESS, Thomas Vaughan: firstname.lastname@example.org.
Funding: Primary funding: This work was primarily funded by NIH grant R01CA136725. Personal support: TLV is supported by NIH Career Development Award K05CA124911. DCW is supported by a Future Fellowship (FT0990987) from the Australian Research Council. SM is supported by an Australian NHMRC Career Development Award and an Australian Research Council Fellowship. YR was supported in part by a grant from the NIH (NIDDK 02956) and the Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Program. Funding of constituent studies: California Tobacco Related Research Program: 3RT-0122, 10RT-0251. Cancer Research UK: C490/A10119, C490/A10124. Swedish Cancer Society: 4559-B01-01XAA, 4758-B02-01XAB. U.S. National Institutes of Health: P01CA091955, R01CA072866, R01CA57947, R01CA59636, R01CA100264, P30CA016672, R01CA133996, P50CA093459, U01CA57949, U01CA57983, U01CA57923, and R01DK63616. Additional funding came from the Medical Research Council, the Cambridge NIHR Biomedical Research Centre and the Cambridge Experimental Cancer Medicine Centre. This study made use of data generated by the Wellcome Trust Case Control Consortium; Funding for the project was provided by the Wellcome Trust under award 076113 and 090355; a full list of the investigators who contributed to the generation of the data is available from the website (http://www.wtccc.org.uk). The Romero Registry Consortium is supported in part by the American Digestive Health Foundation “Endoscopic Research Award,” the American College of Gastroenterology “Junior Faculty Development Award,” the Glaxo Wellcome Inc. Institute for Digestive Health “Clinical Research Award,” and the Miles and Shirley Fiterman Center for Digestive Diseases at Mayo Clinic, Rochester, Minnesota. The Romero Registry also has charitable gifts from five industry partners (Affymetrix, AstraZeneca, Santarus, Takeda and Wyeth.) None of the funding sources had any involvement in the present study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have the following interests. The Romero Registry Consortium is supported in part by the Glaxo Wellcome Inc. Institute for Digestive Health “Clinical Research Award. The Romero Registry also has charitable gifts from five industry partners (Affymetrix, AstraZeneca, Santarus, Takeda and Wyeth.) The authors have received funding from commercial sources: Glaxo Wellcome Inc, Affymetrix, AstraZeneca, Santarus, Takeda and Wyeth, but these funding sources had no influence on the contents of the study. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Abbreviations: CYP19A1, Aromatase; BO, Barrett’s oesophagus; CD38, Cyclic ADP ribose hydrolase glycoprotein; OAC, Oesophageal adenocarcinoma; ESR1, Oestrogen receptor alpha; ESR2, Oestrogen receptor beta; GWAS, Genome-wide association study; OXT, Oxytocin protein; OXTR, Oxytocin receptor; VEGAS, Versatile gene-based test association study
Oesophageal adenocarcinoma (OAC) and its premalignant condition Barrett’s oesophagus (BO) have become increasingly common in the West during the last few decades.[1, 2] The up to 9:1 male-to-female ratio in OAC remains virtually unexplained.[1, 3]
It has been hypothesised that the female sex hormone oestrogen may counteract the development of OAC, a hypothesis supported by a 20 year delay in the onset of this cancer in women compared to men, and a particularly high male-to-female ratio during women’s reproductive years, compared to older ages. A possible mechanism of oestrogen on OAC cells remains to be determined, but the presence of oestrogen receptors has repeatedly been shown in OAC,[6, 7] and a recent experimental study found that OAC and BO cells respond to treatment with selective oestrogen receptor ligands by decreased cell growth and apoptosis. The hypothesis of oestrogen protection has, however, not been unequivocally supported in human studies on pharmacologically exposed individuals or on phenotypes reflecting presumed natural variation in oestrogen levels. The low incidence of OAC in women and the uncertainty about the validity of assumptions concerning oestrogen exposure have been of major concern in previous studies. In the absence of methods for assessment of the integrated steroid exposure given the diurnal and age-dependent within-person variation, assessment of genetic variants may be an alternative measure to assess oestrogen exposure.[9, 10] To the best of our knowledge, no previous study has addressed variants in genes known to regulate oestrogen levels in relation to risk of OAC or BO.
As an increased duration of breastfeeding among women is associated with a substantially decreased risk of OAC,[11, 12] oxytocin is another conceivable mediator of the gender difference. Oxytocin levels are much higher in women than in men, and the hormone is richly released during breastfeeding. Moreover, oxytocin receptors have been identified in the human gastrointestinal tract. In addition, living without a partner is linked with an increased risk of OAC, and oxytocin release is stimulated by physical contacts and interactions between people. Higher oxytocin levels have also been shown to correlate with faster wound healing and less inflammation. A plausible biological mechanism for any protective effect against OAC or BO is that the smooth muscle-contracting oxytocin might raise the lower oesophageal sphincter pressure and counteract gastroesophageal reflux, the strongest known risk factor for OAC and BO.[17–19] We therefore hypothesised that high oxytocin activity might decrease the risk of OAC and BO. Oxytocin has a short half-life in serum, making serum level testing too unstable for research purposes, but polymorphisms in genes coding for oxytocin and its receptor might provide a marker of low oxytocin activity according to studies of behaviour and health in humans.[20–22]
To test the oestrogen and oxytocin hypotheses, we studied associations between single nucleotide polymorphisms (SNPs) in key genes coding for the oestrogen and oxytocin pathways in relation to the risks of OAC and BO.
Materials and Methods
Each study participant provided written informed consent to take part in the research, and the study was approved by the Fred Hutchinson Cancer Research Center Institutional Review Board in Seattle, WA. USA (number 7030, date 8/8/2014). We used harmonised data from the Barrett’s and Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS), a recent genome-wide association study (GWAS) conducted by the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON). Included in the present analysis were all individuals contributed by investigators in the BEACON consortium to the BEAGESS. These individuals were of white-European ancestry, representing 14 cohort and case-control studies from three continents, Australia, Europe (England, Ireland and Sweden), and North America (Canada and United States) (S1 Text and S1 Table). Most of these studies were population-based, and have recently been included in pooled genetic studies.[23, 24] The data were used to study the association between SNPs in three key genes in the oestrogen pathway and three key genes in the oxytocin pathway. The selected genes in the oestrogen pathway were: 1) ESR1, coding for the oestrogen receptor alpha, 2) ESR2, coding for the oestrogen receptor beta, and 3) CYP19A1, coding for aromatase, an enzyme that catalyses the conversion of androgen to oestrogen. The selected genes coding for the oxytocin pathway included: 1) OXTR, coding for the oxytocin receptor, 2) OXT, coding for the oxytocin peptide, and 3) CD38, coding for the oxytocin secretion regulator cyclic ADP ribose hydrolase. The SNPs included in the study are presented in S2 Table.
Genotyping of DNA from buffy coat or whole blood was performed using the Illumina HumanOmni1-Quad platform. Annotations were based on version H of the Illumina product files and corresponded to the Genome Reference Consortium GRCh37 release. Samples with call rate <95% that either were an admixture of more than one DNA (n = 18), had low DNA input and a weak signal (n = 10), or were a noisy or poor quality sample (n = 4) were removed from further analysis. The remaining 6448 samples, including HapMap controls (n = 68) and duplicate samples (n = 67), underwent QA/QC steps as follows. We evaluated batch and plate effects using intensity data and allelic frequency and checked for case-control associations with different experimental factors. No important batch or plate effects or case-control associations with experimental factors were found. We used heterozygosity, sex chromosome intensity data, identity by descent (IBD) analysis and visualisation of B allele frequency (BAF) and log R ratio (LRR) plots to identify samples that had one or more of misannotated sex, unexpected relatedness, or were sample mixtures. Two sample mixtures were removed from further analysis. In the case of misannotated sex or unexpected relatedness, if the source of the discrepancy could be uncovered, the samples were kept; otherwise they were removed (n = 47) from further analysis. After further removing HapMap controls, duplicates and individuals with a missing call rate >2%, 6,061 BEAGESS samples remained for final analysis: 1,508 OAC cases, 2,383 BO cases, and 2,170 controls.
SNPs were excluded if they had a missing call rate >5%, Hardy Weinberg equilibrium p-value among controls ≤1e-4, a discordance among any of the duplicate pairs, a Mendelian error, or a minor allele frequency <1%. After QA/QC a total of 802,272 SNPs remained and were used for the initial GWAS analysis from which we selected 394 SNPs located within the selected genes for use in the versatile gene-based test association study (VEGAS) analysis described below.
Case-control analyses were conducted with an additive logistic regression model where case status was regressed on each SNP genotype. OAC and BO were analysed separately, but since these conditions have a shared genetic background, we also analysed a combined case category (phenotype OAC+BO) to increase power. The included covariates were sex, age and the first four principal components eigenvectors from a principal component analysis (PCA). The eigenvectors were included as covariates to account for population stratification due to ancestry. P-values for each case type (OAC, BO) or OAC and BO combined were calculated for each SNP and used as input for VEGAS. Data were also stratified by sex.
Versatile Gene-Based Test Association Study (VEGAS)
VEGAS provides a gene-based approach that considers association between a trait and all SNPs within a specific gene or a subset of the most significant SNPs (for example the top 90% most significant SNPs), rather than each SNP marker individually, as in a conventional GWAS. Even if the individual effect sizes at any given SNP are small, collectively, all SNPs within a gene could still account for a substantial proportion of variation in risk. Therefore, studies of combined risk alleles might identify candidate genes affecting disease. For some genes, an approach considering all SNPs within each gene might be the most powerful, but for some genes, considering only a subset of the most significant SNPs might be applicable. The true underlying genetic architecture is seldom known in advance and both approaches might be applicable to test. In this study, we first apply the full set of SNPs within each gene, and at a second step we also run VEGAS when including only the top 90% SNPs within each gene to remove non informative SNPs. Since the test including all SNPs and the one that included 90% top SNPs were highly correlated, we did not correct for this as being a new test. By combining the effects of all, or a subset of SNPs in a gene into a test statistic and correcting for linkage disequilibrium (LD), the gene-based test can assess combined effects between SNPs that would be missed in a GWAS. In this study, VEGAS was used to test whether there were any statistically significant effects for genes known to regulate oestrogen or oxytocin levels in OAC and BO patients. In brief, VEGAS explore associations on a per-gene basis using the p-values from all SNPs within a defined gene. An overlap of 10kb (upstream and downstream of the gene) for each gene was used. VEGAS corrects for LD as well as the number of SNPs within each gene. VEGAS takes account of LD between markers in a gene by using simulation based on the LD structure of a set of reference individuals, or, as in this study, using a custom set of individuals whose genotype information was available. A Bonferroni corrected p-value of 0.006 was considered statistically significant since we run 9 tests for each hormone (0.05/9 = 0.0056).
Selected characteristics of the study participants, 1508 OAC case patients, 2383 BO case patients, and 2170 control participants, are presented in Table 1. The distributions of sex and age were similar between these case groups and the control group.
Polymorphisms in the oestrogen pathway.
When including all SNPs within each gene in the gene-based test for the un-stratified data, none of the 3 genes tested showed significant association in both sexes combined (Table 2). However, sex stratified analysis revealed that genetic variants within the gene coding for the oestrogen receptor alpha (ESR1) indicated an increased risk of OAC and BO combined in males (p = 0.0081) (Table 3). When including only the top 90% SNPs within each gene using the VEGAS test, variants in ESR1 were possibly associated with an increased risk of BO and OAC combined in males and females (p = 0.0063) (Table 4). In males, a corresponding potential association was found with BO (p = 0.0058), which was statistically significant with BO and OAC combined (p = 0.0023) (Table 5). The most significant SNP was rs2982684 (located in intron 4), while most other significant SNPs were located in introns 3 and 4 (S3 Table and S4 Table). Polymorphisms in the other two studied genes in the oestrogen pathway did not reach a statistically significant level of association with BO, OAC or OAC or BO, independent of sex stratification or inclusion of top 90% SNPs within each gene (Tables 2 and 3; Tables 4 and 5).
P-values in bold are statistically significant after correction for multiple testing.
P-values in bold are statistically significant.
P-values in bold are statistically significant after correction for multiple testing.
Polymorphisms in the oxytocin pathway.
When including all SNPs within each gene in the gene-based test for the non-stratified data, none of the 3 genes tested in the oxytocin pathways showed significant association after correcting for multiple testing (Table 2). However, the sex stratified analyses showed that genetic variants within the oxytocin receptor gene (OXTR) were statistically borderline associated with BO in males (p = 0.0081). Moreover, when including only the top 90% SNPs within each gene, OXTR variants were significantly associated to BO in both sexes combined (p = 0.0035) and in males separately (p = 0.0012) (Tables 4 and 5). The most significant OXTR SNP was rs237902 (S5 Table). Polymorphisms in the other two studied genes in the oxytocin pathway did not reach a statistically significant level of association with BO, OAC or OAC or BO, independent of sex stratification or inclusion of top 90% SNPs within each gene (Tables 2 and 3; Tables 4 and 5).
This study demonstrated possible associations between SNPs in ESR1 and risk of BO and OAC, and SNPs in OXTR and risk of BO. The other four genes tested, i.e. ESR2 and CYP19A1 in the oestrogen pathway and OXT and CD38 in the oxytocin pathway, did not show any statistically significant association with OAC or BO.
Strengths of this study include the population-based design of the included studies, the extensive data on genetic variants through the assessment of SNPs of relevant genes, and a sample size that exceeds that in most previous studies concerned with BO and OAC. Yet, the low number of female cases of OAC and BO makes it difficult to assess potential associations in females only or to ascertain any potential differences in associations between men and women. Chance findings from multiple testing is a threat to many genetic studies, but our strictly defined hypotheses and the selection of analysis of only three key genes for each hypothesis counteract such errors. Moreover, all results were corrected for multiple testing in the statistical analyses. We used Bonferroni correction for the number of genes tested for each hormone, which is an established method in this respect, and such approach does not need the same low p-value as for a GWAS that needs to correct for 1M tests. Nevertheless, chance cannot be dismissed as a potential explanation for the positive associations identified. Limited statistical power might be the reason for the lack of statistically significant associations among females. A fraction of variance for each gene will remain unexplained, to which rare variants may contribute. To discover rare variants and test them for association with a phenotype, a follow up study could re-sequence a small initial sample size and then genotype the discovered variants in a larger sample set. Finally, the study was based on individuals of white-European ancestry, and the results might not be generalizable to other populations.
Gene-based tests for association are increasingly being seen as useful complements to GWAS. A gene-based approach considers association between a trait and all markers, or a subset of markers, within a specific gene rather than each marker individually, as in a GWAS. VEGAS assigns SNPs to each of 17,787 autosomal genes according to positions on the UCSC Genome Browser hg19 assembly. To capture regulatory regions and SNPs in LD, we defined gene boundaries as 10 kb. Depending on the underlying genetic architecture, gene-based approaches can be more powerful than traditional individual SNP-based GWAS. For example, if a gene contains more than one causative variant, several SNPs within that gene might show marginal effects that are often indistinguishable from random noise in the GWAS results. However, under some genetic architecture, a more powerful gene based method may be to consider only the top most significant SNPs in a gene rather than the full set of SNPs. In this study, we applied both these methods and confirmed a significant effect for ESR1 and OXTR when including only the top 90% SNPs for each gene.
There are, to the best of our knowledge, no previous genetic studies that have addressed the hypotheses tested in the present study. The biological effects of oestrogen are mediated by two distinct oestrogen receptors, alpha and beta, and these exist in both sexes. These receptors often exert opposite effects on cellular processes that differentially influence the development and the progression of cancer. The oestrogen receptor alpha, of particular relevance in this study, is associated with aberrant proliferation, inflammation and cancer development. The finding of an association between SNPs in the gene coding for the oestrogen receptor alpha and an association to BO is therefore interesting. This finding suggests the possibility that a functioning oestrogen pathway might act against OAC development, and therefore possibly be involved in explaining the lower incidence of this tumour in females. There were, however, a too limited number of female cases to assess potential differences in associations between the sexes. Nevertheless, although oestrogen levels are lower in men than women, the results indicate that the oestrogen pathway might be involved in the aetiology of malignant progression also in males. Previous research has found a role for genetic variations in the ESR1 gene in determining post-menopausal plasma oestrogen levels in women.
The finding of an increased risk of BO with variants of the OXTR is in line with the study hypothesis. The oxytocin receptor binds to G proteins which enables oxytocin to activate multiple responses in the cell. The oxytocin system, i.e. oxytocin and the oxytocin receptor, can influence the growth modulation of various neoplastic cells by stimulating or inhibiting cell proliferation, depending on the characteristics and conditions of the cell. Oxytocin can inhibit proliferation of neoplastic cells of other epithelial origin, e.g. in the ovary, endometrium, prostate, bone, breast, and in neuroblastoma and glial tumours. Oxytocin can increase the intracellular concentration of cAMP resulting in decreased proliferation, a mechanism that might be relevant for the association with BO in the present study, but further research is needed. It is also not proven that the investigated SNPs in the oxytocin pathway actually affect the serum levels or activity of this hormone, although previous research indicates that such gene variants can influence oxytocin activity in humans,[20–22] which lends some support for this genetic approach to assess levels of oxytocin as exposure.
Regarding single SNP-associations it seems likely that the association from the gene-based analysis of ESR1 and risk of OAC or BO in men is mainly due to the most significant SNP, rs2982684, located in intron 4, together with other SNPs spanning introns 3 and 4. Intriguingly in this context is that several previous studies have reported associations between SNPs in intron 4 of ESR1 and oestrogen-dependent traits,[35–39] including breast cancer risk. The most significant OXTR SNP in the present study, rs237902 is located in exon 3 and has previously been associated with behavioural phenotypes,[40, 41] as well as susceptibility to preterm birth. However, the functional relevance of this SNP remains to be clarified.
The results of the present study require confirmation in future studies based on very large sample sizes. In the absence of an at least equally large sample population, we tried to replicate our positive findings in an independent cohort from the United Kingdom, including 851 BO cases and 977 OAC cases (47% of the total case number of the present study), and 2785 control subjects from the 1958 British Birth Cohort who were genotyped on a custom version of the Illumina Human1.2M-Duo array. This array comprised less SNPs in each of the candidate genes compared to the Illumina HumanOmni-1-Quad array used for the BEAGESS sample. We analysed the replication dataset in a similar fashion as the main study, but none of the associations between SNPs in ESR1 and OXTR in relation to risk to BO or OAC replicated. The lack of replication might be due to that the positive findings from the main dataset were a result of chance errors. However, the lack of replication was not entirely unexpected due to the limited size of the replication sample. Thus, replication in a larger sample is needed.
In conclusion, this large-scale study of polymorphisms in genes coding for the oestrogen and oxytocin pathways provides some evidence that variants in genes coding the oestrogen receptor alpha and the oxygen receptor might be associated with the risk of BO, OAC, and BO or OAC. These findings indicate a possible hormonal influence in the sex difference in incidence of BO and OAC, but the results need to be cautiously interpreted and require confirmation in future large-scale studies.
Named individuals: We thank Georgia Green Patricia Christopherson, Paul Hansen, Lorna Nolan, and Terri Watson for their efforts in project management and organisation of bio specimens and data. Primary funding: This work was primarily funded by NIH grant R01CA136725. Personal support: TLV is supported by NIH Career Development Award K05CA124911. DCW is supported by a Future Fellowship (FT0990987) from the Australian Research Council. SM is supported by an Australian NHMRC Career Development Award and an Australian Research Council Fellowship. YR was supported in part by a grant from the NIH (NIDDK 02956) and the Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Program. Funding of constituent studies: California Tobacco Related Research Program: 3RT-0122, 10RT-0251. Cancer Research UK: C490/A10119, C490/A10124. Swedish Cancer Society: 4559-B01-01XAA, 4758-B02-01XAB. U.S. National Institutes of Health: P01CA091955, R01CA072866, R01CA57947, R01CA59636, R01CA100264, P30CA016672, R01CA133996, P50CA093459, U01CA57949, U01CA57983, U01CA57923, and R01DK63616. Additional funding from the Medical Research Council, the Cambridge NIHR Biomedical Research Centre and the Cambridge Experimental Cancer Medicine Centre. This study made use of data generated by the Wellcome Trust Case Control Consortium: Funding for the project was provided by the Wellcome Trust under award 076113 and 090355; a full list of the investigators who contributed to the generation of the data is available from the website (http://www.wtccc.org.uk). The Romero Registry Consortium is supported in part by the American Digestive Health Foundation “Endoscopic Research Award,” the American College of Gastroenterology “Junior Faculty Development Award,” the Glaxo Wellcome Inc. Institute for Digestive Health “Clinical Research Award,” and the Miles and Shirley Fiterman Center for Digestive Diseases at Mayo Clinic, Rochester, Minnesota. The Romero Registry also has charitable gifts from five industry partners (Affymetrix, AstraZeneca, Santarus, Takeda and Wyeth.) None of the funding sources had any involvement in the present study.
Conceived and designed the experiments: KL WEE DL WC LB AC HR NJS NCB BJR DAC LJH AHW RCF PP CC YR TLV SMG DW LW ON JL. Performed the experiments: KL WEE DL WC LB AC HR NJS NCB BJR DAC LJH AHW RCF PP CC YR TLV SMG DW LW ON JL. Analyzed the data: WEE. Contributed reagents/materials/analysis tools: KL WEE DL WC LB AC HR NJS NCB BJR DAC LJH AHW RCF PP CC YR TLV SMG DW LW ON JL. Wrote the paper: KL WEE DL WC LB AC HR NJS NCB BJR DAC LJH AHW RCF PP CC YR TLV SMG DW LW ON JL.
- 1. Edgren G, Adami HO, Weiderpass Vainio E, Nyren O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 2013;62(10):1406–14. Epub 2012/08/25. pmid:22917659.
- 2. Alexandropoulou K, van Vlymen J, Reid F, Poullis A, Kang JY. Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study. European journal of gastroenterology & hepatology. 2013;25(1):15–21. Epub 2012/10/02. pmid:23022985.
- 3. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA: a cancer journal for clinicians. 2013;63(4):232–48. Epub 2013/07/03. pmid:23818335.
- 4. Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KE. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut. 2009;58(1):16–23. pmid:18838486.
- 5. Rutegard M, Shore R, Lu Y, Lagergren P, Lindblad M. Sex differences in the incidence of gastrointestinal adenocarcinoma in Sweden 1970–2006. Eur J Cancer. 2010;46(6):1093–100. Epub 2010/03/02. pmid:20188539.
- 6. Akgun H, Lechago J, Younes M. Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus. Anticancer research. 2002;22(3):1459–61. pmid:12168823.
- 7. Chandanos E, Lagergren J. The mystery of male dominance in oesophageal cancer and the potential protective role of oestrogen. Eur J Cancer. 2009;45(18):3149–55. pmid:19804965.
- 8. Sukocheva OA, Wee C, Ansar A, Hussey DJ, Watson DI. Effect of estrogen on growth and apoptosis in esophageal adenocarcinoma cells. Dis Esophagus. 2012. Epub 2012/11/21. pmid:23163347.
- 9. Grover S, Talwar P, Baghel R, Kaur H, Gupta M, Gourie-Devi M, et al. Genetic variability in estrogen disposition: Potential clinical implications for neuropsychiatric disorders. American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics. 2010;153B(8):1391–410. Epub 2010/10/05. pmid:20886541.
- 10. Schuit SC, de Jong FH, Stolk L, Koek WN, van Meurs JB, Schoofs MW, et al. Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women. European journal of endocrinology / European Federation of Endocrine Societies. 2005;153(2):327–34. Epub 2005/08/03. pmid:16061840.
- 11. Cronin-Fenton DP, Murray LJ, Whiteman DC, Cardwell C, Webb PM, Jordan SJ, et al. Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis. Eur J Cancer. 2010;46(11):2067–76. pmid:20456945.
- 12. Bodelon C, Anderson GL, Rossing MA, Chlebowski RT, Ochs-Balcom HM, Vaughan TL. Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. Cancer prevention research. 2011;4(6):840–50. Epub 2011/04/21. pmid:21505180; PubMed Central PMCID: PMC3107894.
- 13. Viero C, Shibuya I, Kitamura N, Verkhratsky A, Fujihara H, Katoh A, et al. REVIEW: Oxytocin: Crossing the bridge between basic science and pharmacotherapy. CNS neuroscience & therapeutics. 2010;16(5):e138–56. Epub 2010/07/16. pmid:20626426; PubMed Central PMCID: PMC2972642.
- 14. Monstein HJ, Grahn N, Truedsson M, Ohlsson B. Oxytocin and oxytocin-receptor mRNA expression in the human gastrointestinal tract: a polymerase chain reaction study. Regulatory peptides. 2004;119(1–2):39–44. Epub 2004/04/20. pmid:15093695.
- 15. Jansson C, Johansson AL, Nyren O, Lagergren J. Socioeconomic factors and risk of esophageal adenocarcinoma: a nationwide Swedish case-control study. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1754–61. pmid:16030113.
- 16. Gouin JP, Carter CS, Pournajafi-Nazarloo H, Glaser R, Malarkey WB, Loving TJ, et al. Marital behavior, oxytocin, vasopressin, and wound healing. Psychoneuroendocrinology. 2010;35(7):1082–90. Epub 2010/02/11. pmid:20144509; PubMed Central PMCID: PMC2888874.
- 17. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. The New England journal of medicine. 1999;340(11):825–31. pmid:10080844.
- 18. Rubenstein JH, Taylor JB. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Alimentary pharmacology & therapeutics. 2010;32(10):1222–7. Epub 2010/10/20. pmid:20955441; PubMed Central PMCID: PMC3481544.
- 19. Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus. The American journal of gastroenterology. 2010;105(8):1729, 30–7; quiz 38. Epub 2010/05/21. pmid:20485283; PubMed Central PMCID: PMC2916949.
- 20. Jin D, Liu HX, Hirai H, Torashima T, Nagai T, Lopatina O, et al. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature. 2007;446(7131):41–5. Epub 2007/02/09. pmid:17287729.
- 21. Walum H, Lichtenstein P, Neiderhiser JM, Reiss D, Ganiban JM, Spotts EL, et al. Variation in the oxytocin receptor gene is associated with pair-bonding and social behavior. Biological psychiatry. 2012;71(5):419–26. Epub 2011/10/22. pmid:22015110; PubMed Central PMCID: PMC3266986.
- 22. Johansson A, Bergman H, Corander J, Waldman ID, Karrani N, Salo B, et al. Alcohol and aggressive behavior in men—moderating effects of oxytocin receptor gene (OXTR) polymorphisms. Genes, brain, and behavior. 2012;11(2):214–21. Epub 2011/10/20. pmid:22008269.
- 23. Levine DM, Ek WE, Zhang R, Liu X, Onstad L, Sather C, et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nature genetics. 2013;45(12):1487–93. Epub 2013/10/15. pmid:24121790; PubMed Central PMCID: PMC3840115.
- 24. Ek WE, Levine DM, D'Amato M, Pedersen NL, Magnusson PK, Bresso F, et al. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux. Journal of the National Cancer Institute. 2013;105(22):1711–8. Epub 2013/10/31. pmid:24168968; PubMed Central PMCID: PMC3833931.
- 25. Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM, et al. A versatile gene-based test for genome-wide association studies. American journal of human genetics. 2010;87(1):139–45. Epub 2010/07/06. pmid:20598278; PubMed Central PMCID: PMC2896770.
- 26. Konda VJ, Waxman I. Endotherapy for Barrett's esophagus. The American journal of gastroenterology. 2012;107(6):827–33. Epub 2012/04/11. pmid:22488078.
- 27. Nilsson S, Gustafsson JA. Estrogen receptors: therapies targeted to receptor subtypes. Clinical pharmacology and therapeutics. 2011;89(1):44–55. Epub 2010/12/03. pmid:21124311.
- 28. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nature reviews. 2011;11(8):597–608. Epub 2011/07/23. pmid:21779010.
- 29. Morita T, Shibata K, Kikkawa F, Kajiyama H, Ino K, Mizutani S. Oxytocin inhibits the progression of human ovarian carcinoma cells in vitro and in vivo. International journal of cancer Journal international du cancer. 2004;109(4):525–32. Epub 2004/03/03. pmid:14991573.
- 30. Cassoni P, Fulcheri E, Carcangiu ML, Stella A, Deaglio S, Bussolati G. Oxytocin receptors in human adenocarcinomas of the endometrium: presence and biological significance. The Journal of pathology. 2000;190(4):470–7. Epub 2000/03/04. pmid:10699997.
- 31. Whittington K, Connors B, King K, Assinder S, Hogarth K, Nicholson H. The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate. The Prostate. 2007;67(10):1132–42. Epub 2007/05/12. pmid:17492653.
- 32. Novak JF, Judkins MB, Chernin MI, Cassoni P, Bussolati G, Nitche JA, et al. A plasmin-derived hexapeptide from the carboxyl end of osteocalcin counteracts oxytocin-mediated growth inhibition [corrected] of osteosarcoma cells. Cancer research. 2000;60(13):3470–6. Epub 2000/07/26. pmid:10910058.
- 33. Cassoni P, Sapino A, Negro F, Bussolati G. Oxytocin inhibits proliferation of human breast cancer cell lines. Virchows Archiv: an international journal of pathology. 1994;425(5):467–72. Epub 1994/01/01. pmid:7850070.
- 34. Cassoni P, Sapino A, Stella A, Fortunati N, Bussolati G. Presence and significance of oxytocin receptors in human neuroblastomas and glial tumors. International journal of cancer Journal international du cancer. 1998;77(5):695–700. Epub 1998/08/04. pmid:9688301.
- 35. Velasco J, Hernandez JL, Perez-Castrillon JL, Zarrabeitia MT, Alonso MA, Gonzalez-Macias J, et al. Haplotypes of intron 4 of the estrogen receptor alpha gene and hip fractures: a replication study in Caucasians. BMC medical genetics. 2010;11:16. Epub 2010/01/30. pmid:20109228; PubMed Central PMCID: PMC2837017.
- 36. Dunning AM, Healey CS, Baynes C, Maia AT, Scollen S, Vega A, et al. Association of ESR1 gene tagging SNPs with breast cancer risk. Human molecular genetics. 2009;18(6):1131–9. Epub 2009/01/08. pmid:19126777; PubMed Central PMCID: PMC2722230.
- 37. Dahlgren A, Lundmark P, Axelsson T, Lind L, Syvanen AC. Association of the estrogen receptor 1 (ESR1) gene with body height in adult males from two Swedish population cohorts. PloS one. 2008;3(3):e1807. Epub 2008/03/20. pmid:18350145; PubMed Central PMCID: PMC2265544.
- 38. Keene KL, Mychaleckyj JC, Smith SG, Leak TS, Perlegas PS, Langefeld CD, et al. Comprehensive evaluation of the estrogen receptor alpha gene reveals further evidence for association with type 2 diabetes enriched for nephropathy in an African American population. Human genetics. 2008;123(4):333–41. Epub 2008/02/29. pmid:18305958; PubMed Central PMCID: PMC2752813.
- 39. Tobias JH, Steer CD, Vilarino-Guell C, Brown MA. Effect of an estrogen receptor-alpha intron 4 polymorphism on fat mass in 11-year-old children. The Journal of clinical endocrinology and metabolism. 2007;92(6):2286–91. Epub 2007/04/05. pmid:17405848.
- 40. Levran O, Randesi M, Li Y, Rotrosen J, Ott J, Adelson M, et al. Drug addiction and stress-response genetic variability: association study in African Americans. Annals of human genetics. 2014;78(4):290–8. Epub 2014/04/29. pmid:24766650; PubMed Central PMCID: PMC4065216.
- 41. Stankova T, Eichhammer P, Langguth B, Sand PG. Sexually dimorphic effects of oxytocin receptor gene (OXTR) variants on Harm Avoidance. Biology of sex differences. 2012;3(1):17. Epub 2012/08/01. pmid:22846218; PubMed Central PMCID: PMC3472235.
- 42. Kim J, Stirling KJ, Cooper ME, Ascoli M, Momany AM, McDonald EL, et al. Sequence variants in oxytocin pathway genes and preterm birth: a candidate gene association study. BMC medical genetics. 2013;14:77. Epub 2013/07/31. pmid:23889750; PubMed Central PMCID: PMC3737028.
- 43. Wellcome Trust Case Control C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447(7145):661–78. Epub 2007/06/08. pmid:17554300; PubMed Central PMCID: PMC2719288.